{"denomUnitsSelected":"Participants","description":"Time from initiation of daratumumab-based combination regimen until death or last follow-up date (whichever occurs first).","reportingStatus":"NOT_POSTED","timeFrame":"Up to 3 years after start of study treatment","title":"Overall Survival (OS)","type":"SECONDARY"}